Bengaluru, Jan. 12 -- The shares of this company, engaged in the manufacturing of a wide range of oncology (anti-cancer) drugs in India, having its operations in the domestic and export markets, are in focus after the company made an announcement for a key acquisition, which we will discuss in this article.

As of Q2 FY26, Ashish Kacholia holds a 5.78 percent stake in the business. His stake remains unchanged in the company since FY23. However, he increased his stake from 5.72 percent in march 2023 to 5.78 percent.

With a market capitalisation of Rs 1,565 crore, the shares of Beta Drugs Ltd reached a day's high of Rs 1,653.10 per share, up over 4 percent from its previous day's closing price of Rs 1,585 per share. Over the past five year...